Press releases
- ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
- ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
- N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
- ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
- ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
More ▼
Key statistics
On Friday, Immunitybio Inc (26CA:DUS) closed at 6.00, -9.15% below its 52-week high of 6.60, set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.82 |
---|---|
High | 6.00 |
Low | 4.68 |
Bid | 6.80 |
Offer | 6.92 |
Previous close | 4.60 |
Average volume | 2.81k |
---|---|
Shares outstanding | 673.95m |
Free float | 137.03m |
P/E (TTM) | -- |
Market cap | 4.95bn USD |
EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:30 BST.
More ▼